These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 16978238)

  • 21. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Spigel DR; Barton J; Farley C; Schreeder M; Hon J; Greco FA
    Cancer; 2008 Aug; 113(4):765-71. PubMed ID: 18543319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
    Wolf J; Richardson PG; Schuster M; LeBlanc A; Walters IB; Battleman DS
    Clin Adv Hematol Oncol; 2008 Oct; 6(10):755-60. PubMed ID: 18997666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib.
    Sood R; Carloss H; Kerr R; Lopez J; Lee M; Druck M; Walters IB; Noga SJ
    Am J Hematol; 2009 Oct; 84(10):657-60. PubMed ID: 19731393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thalidomide in refractory and relapsing multiple myeloma.
    Bladé J; Esteve J; Rosiñol L; Perales M; Montoto S; Tuset M; Montserrat E
    Semin Oncol; 2001 Dec; 28(6):588-92. PubMed ID: 11740814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.
    Mileshkin L; Stark R; Day B; Seymour JF; Zeldis JB; Prince HM
    J Clin Oncol; 2006 Sep; 24(27):4507-14. PubMed ID: 16940275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment.
    Maisnar V; Radocha J; Büchler T; Bláha V; Malý J; Hájek R
    Eur J Haematol; 2007 Oct; 79(4):305-9. PubMed ID: 17803678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
    Min CK; Lee MJ; Eom KS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Lim J; Kim Y; Han K
    Jpn J Clin Oncol; 2007 Dec; 37(12):961-8. PubMed ID: 18156171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
    Pönisch W; Rozanski M; Goldschmidt H; Hoffmann FA; Boldt T; Schwarzer A; Ritter U; Rohrberg R; Schwalbe E; Uhlig J; Zehrfeld T; Schirmer V; Haas A; Kreibich U; Niederwieser D;
    Br J Haematol; 2008 Oct; 143(2):191-200. PubMed ID: 18752593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Velcade in multiple myeloma].
    Votiakova OM; Osmanov DSh; Demina EA; Falaleeva NA; Bialik TE; Riabukhina IuE; Timofeeva OL; Gromova EG; Kupryshina NA; Kochergina NV
    Ter Arkh; 2007; 79(7):70-3. PubMed ID: 17802795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived.
    Corso A; Varettoni M; Mangiacavalli S; Zappasodi P; Pica GM; Algarotti A; Pascutto C; Lazzarino M
    Eur J Haematol; 2009 Nov; 83(5):449-54. PubMed ID: 19519727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
    Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
    Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The efficacy of thalidomide for multiple myeloma: a clinical analysis of 102 Chinese patients].
    Qi PJ; Wang YF; Xu Y; Li YN; Zou DH; Zhao YZ; Xiao ZJ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):226-9. PubMed ID: 18843974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma.
    Dubois D; Dhawan R; van de Velde H; Esseltine D; Gupta S; Viala M; de la Loge C
    J Clin Oncol; 2006 Feb; 24(6):976-82. PubMed ID: 16432077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.
    Prince HM; Mileshkin L; Roberts A; Ganju V; Underhill C; Catalano J; Bell R; Seymour JF; Westerman D; Simmons PJ; Lillie K; Milner AD; Iulio JD; Zeldis JB; Ramsay R
    Clin Cancer Res; 2005 Aug; 11(15):5504-14. PubMed ID: 16061867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of multiple myeloma: an emphasis on new developments.
    Kyle RA; Vincent Rajkumar S
    Ann Med; 2006; 38(2):111-5. PubMed ID: 16581696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor activity of thalidomide in refractory multiple myeloma.
    Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeddis J; Barlogie B
    N Engl J Med; 1999 Nov; 341(21):1565-71. PubMed ID: 10564685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuropathy in multiple myeloma treated with thalidomide: a prospective study.
    Plasmati R; Pastorelli F; Cavo M; Petracci E; Zamagni E; Tosi P; Cangini D; Tacchetti P; Salvi F; Bartolomei I; Michelucci R; Tassinari CA
    Neurology; 2007 Aug; 69(6):573-81. PubMed ID: 17679676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
    Fisher RI; Bernstein SH; Kahl BS; Djulbegovic B; Robertson MJ; de Vos S; Epner E; Krishnan A; Leonard JP; Lonial S; Stadtmauer EA; O'Connor OA; Shi H; Boral AL; Goy A
    J Clin Oncol; 2006 Oct; 24(30):4867-74. PubMed ID: 17001068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Bortezomib in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma].
    Yuan ZG; Hou J; Zhou F; Fu WJ; Chen YB; Xi H; Yang SL
    Zhonghua Xue Ye Xue Za Zhi; 2006 Oct; 27(10):653-5. PubMed ID: 17343194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolving role of novel agents for maintenance therapy in myeloma.
    Magarotto V; Palumbo A
    Cancer J; 2009; 15(6):494-501. PubMed ID: 20010169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.